Oxford Biomedica's Free Webinar on AAV Expertise
![Oxford Biomedica's Free Webinar on AAV Expertise](https://investorshangout.com/images/blog/ihnews-Oxford%20Biomedica%27s%20Free%20Webinar%20on%20AAV%20Expertise.jpg)
Oxford Biomedica Announces Free Webinar on AAV Expertise
Oxford Biomedica, a leading cell and gene therapy CDMO, is set to host a free 60-minute webinar to showcase its advanced capabilities in adeno-associated virus (AAV) development. The event is designed to provide valuable insights into their recent breakthroughs in AAV technology.
Webinar Details and Key Presenters
The webinar, titled “Advanced AAV Processing and Potency through Characterisation of Capsid and Payload Heterogeneity”, is scheduled for September 11. Participants will hear from esteemed speakers:
Featured Speakers
- Sarah Laughlin-Toth, PhD, Senior Scientist, Analytical Development at Oxford Biomedica
- Thomas Thiers, Downstream Scientist, Purification Sciences at Oxford Biomedica
- Alex Meola, Associate Director, AAV Downstream Process Development at Oxford Biomedica
Significance of AAV Characterisation
The speakers will delve into the importance of advanced characterisation of AAV capsids and discuss how it impacts product quality and efficacy. They will focus on factors such as:
Impact of Capsid Modifications
Topics will include the effects of capsid modifications like VP1 deamidation, bioreactor production conditions, and capsid heterogeneity on AAV products.
This discussion is crucial for enhancing the development and manufacturing processes of AAV-based therapies. Improvements in these areas could lead to better therapeutic efficacy and increased patient safety.
Event Timing and Registration
The webinar will commence at 16:00 BST. Following the presentations will be a live Q&A session, allowing attendees to engage with the experts. Registration can be completed via the company’s official website.
About Oxford Biomedica
Oxford Biomedica plc (LSE: OXB) is a prestigious contract development and manufacturing organization (CDMO) in the cell and gene therapy sector. The company’s mission is to empower its partners in delivering life-altering therapies to patients globally.
With a rich history as pioneers in the field, OXB has over 25 years of expertise in developing and manufacturing viral vectors. The organization collaborates with leading pharmaceutical and biotechnology firms to provide comprehensive solutions in viral vector development, particularly with lentivirus and AAV technologies.
World-Class Manufacturing Capabilities
Oxford Biomedica's capabilities encompass early-stage development all the way to commercialisation, backed by stringent quality assurance, analytical methods, and regulatory knowledge. Their unique technologies include a cutting-edge 4th generation lentiviral vector system and advanced AAV production techniques.
Headquartered in Oxford, UK, Oxford Biomedica operates bioprocessing and manufacturing facilities in various locations, including regions in France and near Boston, MA.
Contact Information
Enquiries:
Oxford Biomedica plc:
Sebastien Ribault, Chief Commercial Officer – T: +44 (0) 1865 509 737 / E: partnering@oxb.com
For further information about Oxford Biomedica's initiatives, visit their official website and follow their updates on social media platforms.
Frequently Asked Questions
What topics will be covered in the Oxford Biomedica webinar?
The webinar will focus on advanced AAV processing and the importance of capsid characterisation in therapy development.
Who are the speakers for this event?
Speakers include Sarah Laughlin-Toth, Thomas Thiers, and Alex Meola from Oxford Biomedica.
What are the benefits of attending the webinar?
Attendees will gain insights into AAV technology advancements that could enhance therapy efficacy and safety.
How can I register for the webinar?
Registration is available through the official Oxford Biomedica website.
What is the mission of Oxford Biomedica?
Oxford Biomedica aims to enable its clients to provide life-changing therapies to patients worldwide.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Southeast Toyota Finance Achieves Top Dealer Satisfaction Ranking
- Beer Cans Market to Surge to USD 19.14 Billion
- Travel Retail Market Growth Expected to Reach $132.95 Billion
- NFL Tuesday Night Gaming Season 3 Announced with Enthusiast Gaming
- West Red Lake Gold Reports High-Grade Drill Intersections
- Point Predictive Unveils IEValidate for Enhanced Verification
- Oil & Gas Pipeline Leak Detection Market Insights
- Cyber Security Market Growth Driven by AI Solutions
- Mental Health App Market Set to Reach USD 17.46 Billion
- Grafted Polyolefins Market Forecasts for Growth and Innovations